ArticleBioengineering (Basel, Switzerland)2025
CAD-Skin: A Hybrid Convolutional Neural Network-Autoencoder Framework for Precise Detection and Classification of Skin Lesions and Cancer.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- MorphoNet: An Interpretable Hierarchical Deep Learning Framework for Multi-Class Skin Lesion Classification Using Dermoscopic Morphology.Bioengineering (Basel, Switzerland) · 2026Article
- Modelling of hybrid deep ensemble learning based skin lesion detection using FCNN denoising and inception-dilated ResNetV2.Scientific reports · 2026Article
- Artificial intelligence in immunotherapy: revolutionizing diagnostic and therapeutic applications in cancer and autoimmune diseases.Clinical and experimental medicine · 2026Review
- AI Advancements in Healthcare: Medical Imaging and Sensing Technologies.Bioengineering (Basel, Switzerland) · 2025Article
- Design of Block-Scrambling-Based privacy protection mechanism in healthcare using fusion of transfer learning models with Hippopotamus optimization algorithm.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cancer is a class of disorder defined by the growth of abnormal cells on the body. Accurately identifying and diagnosing skin lesions is quite difficult because skin malignancies share many common characteristics and a wide range of morphologies. To face this challenge, deep learning algorithms have been proposed. Deep learning algorithms have shown diagnostic efficacy comparable to dermatologists in the discipline of images-based skin lesion diagnosis in recent research articles. This work proposes a novel deep learning algorithm to detect skin cancer. The proposed CAD-Skin system detects and classifies skin lesions using deep convolutional neural networks and autoencoders to improve the classification efficiency of skin cancer. The CAD-Skin system was designed and developed by the use of the modern preprocessing approach, which is a combination of multi-scale retinex, gamma correction, unsharp masking, and contrast-limited adaptive histogram equalization. In this work, we have implemented a data augmentation strategy to deal with unbalanced datasets. This step improves the model's resilience to different pigmented skin conditions and avoids overfitting. Additionally, a Quantum Support Vector Machine (QSVM) algorithm is integrated for final-stage classification. Our proposed CAD-Skin enhances category recognition for different skin disease severities, including actinic keratosis, malignant melanoma, and other skin cancers. The proposed system was tested using the PAD-UFES-20-Modified, ISIC-2018, and ISIC-2019 datasets. The system reached accuracy rates of 98%, 99%, and 99%, consecutively, which is higher than state-of-the-art work in the literature. The minimum accuracy achieved for certain skin disorder diseases reached 97.43%. Our research study demonstrates that the proposed CAD-Skin provides precise diagnosis and timely detection of skin abnormalities, diversifying options for doctors and enhancing patient satisfaction during medical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.